SCHEMBL4497826

SCHEMBL4497826

Nc1ccc2[nH]c(-c3ccccc3-c3nc4cc(Cl)ccc4[nH]3)nc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 10/20 0.51
ALDH1A1 P00352 9/20 0.51
NPC1 O15118 9/20 0.51
RAB9A P51151 9/20 0.51
SMN1; SMN2 Q16637 9/20 0.51
KDM4E B2RXH2 8/20 0.51
MAPT P10636 8/20 0.51
GAA P10253 7/20 0.51
MEN1 O00255 7/20 0.51
KMT2A Q03164 7/20 0.51
HSD17B10 Q99714 6/20 0.51
TP53 P04637 6/20 0.51
APP P05067 1/20 0.51
NFKB1 P19838 1/20 0.51
SNCA P37840 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
MCL1 Q07820 1/20 0.51
GLA P06280 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496081 0.91 ALDH1A1 (0.57) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL30863444 0.91 ALDH1A1 (0.57) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4496268 0.86 ALDH1A1 (0.66) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2690716 0.85 ALDH1A1 (0.51) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL31289554 0.85 NPBWR1 (0.52) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL31289524 0.84 HDAC6 (0.54) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL10041675 0.84 NPC1 (0.62) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL22956044 0.84 KDM4E (0.59) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7393988 0.84 F7 (0.55) HPGDALDH1A1NPC1RAB9AKDM4E
SCHEMBL13405888 0.83 ALDH1A1 (0.71) HPGDALDH1A1NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482373-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2009-01-27 US disclosed
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2007-02-01 US disclosed
US-7132439-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2006-11-07 US disclosed
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 HPGD 3236/4885ALDH1A1 2373/4885NPC1 1216/4885
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 HPGD 3236/4885ALDH1A1 2373/4885NPC1 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.